AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21586792 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin catheter for hysterosalpingography (HSG) during dye injection
Number of subjects: 89
Study 21586792 — intervention group
Group type: COMPARATOR
Intervention: Standard metal cannula for hysterosalpingography (HSG) during dye injection
Number of subjects: 89
Study 18316791 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab
Number of subjects: 463
Study 18316791 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 463
Study 18316791 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment arms
Number of subjects: 463
Study 16594764 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 12449846 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning disabled children (LD)
Number of subjects: 71
Study 12449846 — intervention group
Group type: COMPARATOR
Intervention: Normal children (Control)
Number of subjects: 71
Study 10360765 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-431 (5, 10, 20, 30, and 40 mg)
Number of subjects: 14
Study 10360765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 7585759 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg diltiazem
Number of subjects: 158
Study 7585759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 7585759 — intervention group
Group type: EXPERIMENTAL
Intervention: Titrated diltiazem (200, 300, or 400 mg)
Number of subjects: 158
Study 7585759 — intervention group
Group type: COMPARATOR
Intervention: Titrated placebo
Number of subjects: 158
Study 2037708 — intervention group
Group type: COMPARATOR
Intervention: theophylline 200 mg every 12 hours alone
Number of subjects: 15
Study 2037708 — intervention group
Group type: EXPERIMENTAL
Intervention: theophylline 200 mg every 12 hours with mexiletine 150 mg every 8 hours
Number of subjects: 15
Study 6166800 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg thrice daily
Number of subjects: 17
Study 6166800 — intervention group
Group type: COMPARATOR
Intervention: Pindolol 7.5 mg twice daily
Number of subjects: 17
Study 6166800 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 17
Study 6166800 — intervention group
Group type: COMPARATOR
Intervention: Pindolol
Number of subjects: 17
Study 31152034 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare voucher model (HcV)
Number of subjects: 0
Study 31152034 — intervention group
Group type: COMPARATOR
Intervention: Electronic health card model (eHC)
Number of subjects: 0
Study 28841451 — intervention group
Group type: EXPERIMENTAL
Intervention: Human reminder call in preferred language
Number of subjects: 963
Study 28841451 — intervention group
Group type: COMPARATOR
Intervention: No prior contact (Control)
Number of subjects: 963
Study 26176605 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective low-dose spinal anesthesia
Number of subjects: 100
Study 26176605 — intervention group
Group type: COMPARATOR
Intervention: Intrarectal local anesthesia (IRLA) plus periprostatic nerve blockade (PPNB)
Number of subjects: 100
Study 24445560 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone PCA
Number of subjects: 0
Study 24445560 — intervention group
Group type: COMPARATOR
Intervention: Morphine PCA
Number of subjects: 0
Study 24445560 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 22496893 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cTBS
Number of subjects: 26
Study 22496893 — intervention group
Group type: COMPARATOR
Intervention: Sham cTBS
Number of subjects: 26
Study 19168521 — intervention group
Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 0
Study 19168521 — intervention group
Group type: COMPARATOR
Intervention: Controlled release carvedilol
Number of subjects: 0
Study 19168521 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous aortic flow augmentation device
Number of subjects: 0
Study 19168521 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid hormone analogue
Number of subjects: 0
Study 19168521 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 0
Study 19168521 — intervention group
Group type: COMPARATOR
Intervention: Irbesartan
Number of subjects: 0
Study 19168521 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-interferon
Number of subjects: 0
Study 19168521 — intervention group
Group type: COMPARATOR
Intervention: Mid-regional pro-adrenomedullin
Number of subjects: 0
Study 19168521 — intervention group
Group type: COMPARATOR
Intervention: Dronedarone
Number of subjects: 0
Study 17538106 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic saline (0.9% NaCl)
Number of subjects: 60
Study 17538106 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline (7% NaCl)
Number of subjects: 60
Study 17538106 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile (hypotonic) water
Number of subjects: 60
Study 17538106 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment control
Number of subjects: 60
Study 15326018 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted EBM educational intervention (1 hospital, 17 medical students and residents)
Number of subjects: 119
Study 15326018 — intervention group
Group type: COMPARATOR
Intervention: Control group (2 hospitals, 23 medical students and residents)
Number of subjects: 119
Study 15326018 — intervention group
Group type: COMPARATOR
Intervention: Comparison of change scores between intervention and control groups
Number of subjects: 119
Study 15326018 — intervention group
Group type: COMPARATOR
Intervention: Survey of internal medicine residents
Number of subjects: 119
Study 11430963 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg per day
Number of subjects: 6926
Study 11430963 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg per day
Number of subjects: 6926
Study 11430963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6926
Study 9209608 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 67
Study 9209608 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 67
Study 8425624 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (12 IU/d)
Number of subjects: 6
Study 8425624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 3623678 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine, 20 mg p.o.
Number of subjects: 9
Study 3623678 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 9
Study 3623678 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium infusion
Number of subjects: 9
Study 3623678 — intervention group
Group type: COMPARATOR
Intervention: Control group (low sodium diet)
Number of subjects: 9
Study 31711582 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial validated questionnaire (PCID‐DTO Rios)
Number of subjects: 2815
Study 31711582 — intervention group
Group type: EXPERIMENTAL
Intervention: Legislation regarding presumed consent
Number of subjects: 2815
Study 31711582 — intervention group
Group type: EXPERIMENTAL
Intervention: Year of study, knowing a donor, and attitude toward ODT
Number of subjects: 2815
Study 31711582 — intervention group
Group type: EXPERIMENTAL
Intervention: Interest in attending a talk about ODT
Number of subjects: 2815
Study 27808012 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based exercises (n=17)
Number of subjects: 32
Study 27808012 — intervention group
Group type: COMPARATOR
Intervention: Land-based exercises (n=15)
Number of subjects: 32
Study 25527456 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 2-L dose of Moviprep
Number of subjects: 23
Study 25527456 — intervention group
Group type: EXPERIMENTAL
Intervention: Two separate doses of 1 L of Moviprep
Number of subjects: 23
Study 23355273 — intervention group
Group type: EXPERIMENTAL
Intervention: CHESS (Comprehensive Health Enhancement Support System)
Number of subjects: 285
Study 23355273 — intervention group
Group type: COMPARATOR
Intervention: Internet
Number of subjects: 285
Study 21855837 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged bivalirudin infusion (4-hour infusion after PCI)
Number of subjects: 264
Study 21855837 — intervention group
Group type: COMPARATOR
Intervention: Standard bivalirudin infusion (peri-PCI infusion)
Number of subjects: 264
Study 21855837 — intervention group
Group type: COMPARATOR
Intervention: Heparin plus abciximab
Number of subjects: 264
Study 19247742 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (10 ml 0.5% - 50 mg)
Number of subjects: 60
Study 19247742 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (10 ml 0.25% - 25 mg)
Number of subjects: 60
Study 19247742 — intervention group
Group type: COMPARATOR
Intervention: Group C (40 ml 0.0625% - 25 mg)
Number of subjects: 60
Study 16913337 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly conservative phlebotomy
Number of subjects: 0
Study 16913337 — intervention group
Group type: COMPARATOR
Intervention: Standardized controls
Number of subjects: 0
Study 15229391 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose bolus tirofiban (n = 50)
Number of subjects: 100
Study 15229391 — intervention group
Group type: COMPARATOR
Intervention: Abciximab (n = 50)
Number of subjects: 100
Study 10858175 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 0
Study 10858175 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study 9059096 — intervention group
Group type: EXPERIMENTAL
Intervention: Invos 3100
Number of subjects: 33
Study 9059096 — intervention group
Group type: COMPARATOR
Intervention: Critikon 2020
Number of subjects: 33
Study 8118471 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 60 mg daily
Number of subjects: 72
Study 8118471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 3772579 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who received letters (RL)
Number of subjects: 0
Study 3772579 — intervention group
Group type: COMPARATOR
Intervention: Patients who did not receive letters (NL)
Number of subjects: 0
Study 3377459 — intervention group
Group type: EXPERIMENTAL
Intervention: Carumonam (1 g every 8 h)
Number of subjects: 52
Study 3377459 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin (1 mg/kg every 8 h)
Number of subjects: 52
Study 3377459 — intervention group
Group type: EXPERIMENTAL
Intervention: Carumonam
Number of subjects: 52
Study 3377459 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 52
Study 31335570 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam
Number of subjects: 95
Study 31335570 — intervention group
Group type: COMPARATOR
Intervention: Cefepime
Number of subjects: 95
Study 28710053 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian stimulation plus tamoxifen
Number of subjects: 0
Study 28710053 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian stimulation plus letrozole
Number of subjects: 0
Study 28710053 — intervention group
Group type: COMPARATOR
Intervention: Standard ovarian stimulation
Number of subjects: 0
Study 25767035 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Number of subjects: 28
Study 25767035 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Training (MIT)
Number of subjects: 28
Study 23331982 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress training sessions (experimental group)
Number of subjects: 26
Study 23331982 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stress training)
Number of subjects: 26
Study 21671276 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaced Education (SE) program following the live CME event, consisting of 40 validated questions and explanations covering 4 clinical topics, with repetition intervals of 8- and 16-days based on performance.
Number of subjects: 246
Study 21671276 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group receiving the SE program 18 weeks later.
Number of subjects: 246
Study 19117887 — intervention group
Group type: EXPERIMENTAL
Intervention: Laronidase (recombinant human alpha-l-iduronidase)
Number of subjects: 45
Study 16937109 — intervention group
Group type: EXPERIMENTAL
Intervention: Profylin fluoride gel with buffering components (active gel)
Number of subjects: 12
Study 16937109 — intervention group
Group type: COMPARATOR
Intervention: Profylin fluoride gel without buffering components (placebo gel)
Number of subjects: 12
Study 16937109 — intervention group
Group type: EXPERIMENTAL
Intervention: Rinsing with 0.2% NaF
Number of subjects: 12
Study 16937109 — intervention group
Group type: COMPARATOR
Intervention: Rinsing with water
Number of subjects: 12
Study 16937109 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 12
Study 16366128 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term rehabilitation program (Group A)
Number of subjects: 67
Study 16366128 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation program (Group B)
Number of subjects: 67
Study 11564854 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based participatory research interventions
Number of subjects: 0
Study 9118789 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg ofloxacin and 500 mg metronidazole intravenously, twice daily
Number of subjects: 13
Study 9118789 — intervention group
Group type: COMPARATOR
Intervention: Control group (no initial antibiotics), n = 13
Number of subjects: 13
Study 8335858 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular use of Beconase AQ nasal spray (400 micrograms daily)
Number of subjects: 60
Study 8335858 — intervention group
Group type: COMPARATOR
Intervention: As required (prn) use of Beconase AQ nasal spray
Number of subjects: 60
Study 3726286 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (250 micrograms)
Number of subjects: 10
Study 3726286 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle alone)
Number of subjects: 10
Study 29935863 — intervention group
Group type: COMPARATOR
Intervention: Rifaximin (R-group)
Number of subjects: 120
Study 29935863 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole (M-group)
Number of subjects: 120
Study 26912641 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal-transcranial direct current stimulation
Number of subjects: 26
Study 26912641 — intervention group
Group type: COMPARATOR
Intervention: Sham-transcranial direct current stimulation
Number of subjects: 26
Study 25122693 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus 5-FU, leucovorin and oxaliplatin (Folfox-4) followed by bevacizumab-5-FU-RT before total mesorectal excision (TME)
Number of subjects: 91
Study 25122693 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab-5-FU-RT before TME
Number of subjects: 91
Study 22289150 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-Q2
Number of subjects: 0
Study 22289150 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin
Number of subjects: 0
Study 22289150 — intervention group
Group type: COMPARATOR
Intervention: Sparfloxacin
Number of subjects: 0
Study 22289150 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin
Number of subjects: 0
Study 19070383 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (2.5‐5mg/day)
Number of subjects: 104
Study 19070383 — intervention group
Group type: COMPARATOR
Intervention: ARB (losartan 25‐50mg/day, candesartan 4‐8 mg/day, valsartan 40‐80 mg/day, telmisartan 20‐40 mg/day)
Number of subjects: 104
Study 17454163 — intervention group
Group type: EXPERIMENTAL
Intervention: Phyto‐Female Complex
Number of subjects: 50
Study 17454163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 14757258 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic Therapy
Number of subjects: 706
Study 14757258 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine/Chondroitin
Number of subjects: 706
Study 12380633 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg twice daily
Number of subjects: 283
Study 12380633 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg once daily
Number of subjects: 283
Study 12380633 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 250 mg twice daily
Number of subjects: 283
Study 10541948 — intervention group
Group type: EXPERIMENTAL
Intervention: Variant (TA)7/(TA)7 promoter in normal and G6PD-deficient newborns
Number of subjects: 0
Study 10541948 — intervention group
Group type: COMPARATOR
Intervention: Control subjects from the same population
Number of subjects: 0
Study 7594320 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg/day
Number of subjects: 16
Study 7594320 — intervention group
Group type: COMPARATOR
Intervention: Famotidine 40 mg/day
Number of subjects: 16
Study 2129071 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose glycyrrhizin (Stronger Neo-Minophagen C, SNMC) administered intravenously daily for the first 3 weeks, and every second day for the following 8 weeks. Dosage: 100-200 ml in 21 patients and 400-800 ml in the other 21.
Number of subjects: 42
Study 7380749 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention and methylphenidate (0.25 mg/kg)
Number of subjects: 8
Study 7380749 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention and methylphenidate (0.75 mg/kg)
Number of subjects: 8
Study 7380749 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of methylphenidate after 13 weeks of behavioral intervention
Number of subjects: 8
Study 7380749 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of methylphenidate after 13 weeks of behavioral intervention
Number of subjects: 8
Study 7380749 — intervention group
Group type: EXPERIMENTAL
Intervention: No medication after 13 weeks of behavioral intervention
Number of subjects: 8
Study 7380749 — intervention group
Group type: COMPARATOR
Intervention: Behavioral intervention
Number of subjects: 8
Study 7380749 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent training
Number of subjects: 8
Study 31410968 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month dual antiplatelet therapy (DAPT) with ticagrelor and aspirin followed by 23-month ticagrelor monotherapy
Number of subjects: 15445
Study 31410968 — intervention group
Group type: COMPARATOR
Intervention: Standard 12-month DAPT followed by 12-month aspirin monotherapy
Number of subjects: 15445
Study 31410968 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month DAPT with ticagrelor and aspirin followed by 23-month ticagrelor monotherapy
Number of subjects: 15445
Study 30554789 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 118
Study 30554789 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 118
Study 30554789 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic exercise and resistance exercise
Number of subjects: 118
Study 28364507 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hr nap opportunity at 14:00 following each sleep-restricted night
Number of subjects: 57
Study 28364507 — intervention group
Group type: COMPARATOR
Intervention: No nap (stayed awake)
Number of subjects: 57
Study 28364507 — intervention group
Group type: COMPARATOR
Intervention: Sleep restriction (5-hr time in bed for five nights and 3 nights)
Number of subjects: 57
Study 28364507 — intervention group
Group type: COMPARATOR
Intervention: 9-hr time in bed each night
Number of subjects: 57
Study 26993316 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold stimulus
Number of subjects: 7
Study 26993316 — intervention group
Group type: COMPARATOR
Intervention: Room temperature (RT)
Number of subjects: 7
Study 25081735 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin with additional antihistamine (desloratadine)
Number of subjects: 40
Study 25081735 — intervention group
Group type: COMPARATOR
Intervention: Isotretinoin only
Number of subjects: 40
Study 22472454 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (beta‐carotene, selenium, vitamins C and E) in addition to methimazole
Number of subjects: 0
Study 22472454 — intervention group
Group type: COMPARATOR
Intervention: Methimazole only
Number of subjects: 0
Study 22472454 — intervention group
Group type: COMPARATOR
Intervention: Both groups (test and control)
Number of subjects: 0
Study 19734185 — intervention group
Group type: EXPERIMENTAL
Intervention: nebivolol 5 mg/day
Number of subjects: 27
Study 17308252 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine
Number of subjects: 113
Study 17308252 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermentable fiber
Number of subjects: 113
Study 17308252 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide diet
Number of subjects: 113
Study 17308252 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard enteral formula with Synbiotic 2000
Number of subjects: 113
Study 15350314 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual field progression detected with pointwise linear regression (PLR) analysis.
Number of subjects: 401
Study 15350314 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age at the initial intervention.
Number of subjects: 401
Study 15350314 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger IOP fluctuation.
Number of subjects: 401
Study 15350314 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing number of glaucoma interventions.
Number of subjects: 401
Study 15350314 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer follow-up time.
Number of subjects: 401
Study 15350314 — intervention group
Group type: EXPERIMENTAL
Intervention: IOP fluctuation in eyes with and without a history of cataract extraction.
Number of subjects: 401
Study 11453234 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive glass implantation (test group)
Number of subjects: 38
Study 11453234 — intervention group
Group type: COMPARATOR
Intervention: Flap procedure only (control group)
Number of subjects: 38
Study 9850904 — intervention group
Group type: EXPERIMENTAL
Intervention: Superior corneal incision (Group 1)
Number of subjects: 90
Study 9850904 — intervention group
Group type: EXPERIMENTAL
Intervention: Superior scleral incision (Group 2)
Number of subjects: 90
Study 9850904 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal corneal incision (Group 3)
Number of subjects: 90
Study 8208173 — intervention group
Group type: EXPERIMENTAL
Intervention: Portfolio teaching with tutors (general practitioners or consultants) and longitudinal follow-up of three consenting cancer patients, including bimonthly tutorials.
Number of subjects: 3